January 28, 2021 6:22pm

On patient enrollment and dosing in an ongoing P1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer.

BLCM closed down -$0.04 to $3.84 and has a positive +$2.12 or +55.47% to $5.97

BLCM has satisfactorily addressed all clinical hold issues and may now resume enrollment without modification to the current study protocol. The company plans to work with clinical investigators to resume patient enrollment.


BPX-601 is the first GoCAR-T® product candidate, incorporates iMC, BLCM’s inducible co-activation domain.

  • iMC (inducible MyD88/CD40) is designed to provide a powerful boost to T cell proliferation and persistence, production of immunomodulatory cytokines and enable the CAR-T to override key immune inhibitory mechanisms, including PD-1 and TGF-beta. BPX-601 is being evaluated as a treatment for pancreatic and prostate tumors expressing prostate stem cell antigen (PSCA).